Pharmacological and in vitro evaluation of cyclacillin: assessment as potential single-dose therapy for treatment of Neisseria gonorrhoeae infection.

Abstract

The pharmacokinetic properties of cyclacillin administered as a 3.0-g oral dose, with and without progenecid, have been studied and correlated with in vitro activity of the drug against 109 isolates of Neisseria gonorrhoeae. By 8 h after dosage, levels of cyclacillin in serum declined below the minimal inhibitory concentration and the inferior antibacterial activity of cyclacillin (compared with that of amipicillin) suggest that cyclacillin is not a promising alternative to ampicillin for single-dose treatment of gonorrhea.

• Authors: K F Wagner, A D Blair, G W Counts, K K Holmes
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 17 Issue 1 Pg. 89-91 (Jan 1980) ISSN: 0066-4804 [Print] United States
• PMID: 6766294 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Penicillins
• Cyclacillin
• Ampicillin

Topics

• Adolescent
• Adult
• Ampicillin (pharmacology)
• Cyclacillin (administration & dosage, pharmacology, therapeutic use)
• Gonorrhea (drug therapy)
• Humans
• Male
• Microbial Sensitivity Tests
• Neisseria gonorrhoeae (drug effects)
• Penicillins (pharmacology)